MEGAWALPTWKEEGREQAAGQGEEEECPICTEPYGPRERRLALLNCSHGL CVGCLHRLLGSASSADLGRVRCPLCRQKTPVLEWEICRLQEELLQADGPS RQPRREAPASYHRNPGPWGSLEHRYQLRFLAGPVGGRGCLPFLPCPPCLG ARLWTLRERGPCARRLALLSLLALELLGLLLVFTPLLLLGLLFVLLDRSG R
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Protein concentration is above or equal to 0.05 mg/ml.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
pH: 8.00 Constituents: 0.31% Glutathione, 0.79% Tris HCl
NADPH dependent diflavin oxidoreductase 1
NADPH dependent FMN and FAD containing oxidoreductase
NADPH-dependent diflavin oxidoreductase 1
NADPH-dependent FMN and FAD-containing oxidoreductase
Novel reductase 1
Oxidoreductase that catalyzes the NADP-dependent reduction of cytochrome c and one-electron acceptors, such as doxorubicin, potassium ferricyanide and menadione (in vitro).
Low expression in brain, heart, kidney, pancreas, prostate and skeletal muscle. Highest levels in the placenta. Expressed in cancer cell lines including promyelocytic leukemia, HeLa S3, chronic myelagenous leukemia, lymphoblastic leukemia, Burkitt's lymphoma, colorectal adenocarcinoma, lung carcinoma, and melanoma G361.
In the C-terminal section; belongs to the flavoprotein pyridine nucleotide cytochrome reductase family. Contains 1 FAD-binding FR-type domain. Contains 1 flavodoxin-like domain.
Cytoplasm > perinuclear region. Concentrated in perinuclear structure.